Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.70236 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Kosei Hasegawa und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals.
Abstract (Originalsprache)
Background
In the phase 3 EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first‐line platinum‐based chemotherapy. We present a post hoc subgroup analysis of patients enrolled in Japan.
Methods
Patients were enrolled regardless of programmed cell death‐ligand 1 status and randomized 1:1 to cemiplimab 350 mg intravenously every 3 weeks or investigator's choice single‐agent chemotherapy for up to 96 weeks. Primary endpoint was OS. Key secondary endpoints were progression‐free survival (PFS) and objective response rate (ORR).
Results
Overall, 608 patients were randomized, of whom 56 (9.2%) were in Japan (cemiplimab, n = 29; chemotherapy, n = 27). The median (range) duration of follow‐up was 13.6 (6.0–25.3) versus 18.2 (6.0–38.2) months for patients in Japan and for the overall population, respectively. Median OS (95% confidence interval [CI]) was 8.4 (7.0‐not evaluable) and 9.4 (5.4–14.9) months for cemiplimab versus chemotherapy (hazard ratio [HR]: 0.86; 95% CI: 0.43–1.68). Median PFS (95% CI) was 4.0 (1.4–8.2) versus 3.7 (1.8–4.2) months with cemiplimab and chemotherapy (HR: 0.90; 95% CI: 0.50–1.61), respectively. ORR was 17.2% for cemiplimab and 7.4% for chemotherapy (odds ratio, 2.47; 95% CI, 0.44–13.99). Incidence of treatment‐emergent adverse events at any grade was 79.3% for cemiplimab and 100% for chemotherapy. Grade ≥3 adverse events were 37.9% versus 66.7% with cemiplimab and chemotherapy, respectively.
Discussion
While acknowledging limitations inherent to a small subgroup analysis, the HR of 0.86 observed in Japanese patients suggests an emerging survival benefit despite a 4.6‐month shorter median duration of follow‐up versus the overall study population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
- Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.
- Gynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
- Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Saitama Cancer Center, Saitama, Japan.
ORCID-Profile: Kosei Hasegawa, Kazuhiro Takehara
Förderung
- Sanofi
- Regeneron Pharmaceuticals
Zitieren
APA
Hasegawa, K., Takahashi, S., Ushijima, K., Okadome, M., Yonemori, K., Yokota, H., Vergote, I., Monk, B. J., Tewari, K. S., Fujiwara, K., Li, J., Jamil, S., Paccaly, A., Takehara, K., Usami, T., Aoki, Y., Suzuki, N., Kobayashi, Y., Yoshida, Y., …, & Oaknin, A. (2024). Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70236
Vancouver
Hasegawa K, Takahashi S, Ushijima K, Okadome M, Yonemori K, Yokota H, et al. Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer. Cancer Medicine. 2024. doi:10.1002/cam4.70236
BibTeX
@article{Hasegawa2024,
author = {Hasegawa, Kosei and Takahashi, Shunji and Ushijima, Kimio and Okadome, Masao and Yonemori, Kan and Yokota, Harushige and Vergote, Ignace and Monk, Bradley J and Tewari, Krishnansu S and Fujiwara, Keiichi and Li, Jingjin and Jamil, Shaheda and Paccaly, Anne and Takehara, Kazuhiro and Usami, Tomoka and Aoki, Yoichi and Suzuki, Nao and Kobayashi, Yoichi and Yoshida, Yoshio and Watari, Hidemichi and Seebach, Frank and Lowy, Israel and Mathias, Melissa and Fury, Matthew G and Oaknin, Ana},
title = {Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70236}
}
EUVIMED